www.straitstimes.com ·
Sgh Working With Astar to Commercialise AI Powered Antibiotics Test for Superbugs
Topic context
This topic has been covered 398964 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThis is a research collaboration and early-stage commercialization agreement for a diagnostic test (iACT) targeting drug-resistant infections. The commercial mechanism is weak: no pricing, revenue projections, or production scale are disclosed. The primary impact is on the healthcare diagnostics sector, specifically antibiotic susceptibility testing. The AI component is a secondary feature. No direct scarcity or supply chain disruption is indicated.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- SGH and A*STAR signed a three-year MOU on May 19, 2026 to commercialize iACT.
- iACT has been used 84 times in three years.
- iACT includes 180 proprietary antibiotic combinations and uses AI for analysis.
- SGH signed a two-year agreement with Gyalpozhing College of Information Technology for an AI chest radiograph model.
- The AI chest radiograph model is expected to launch in 2027.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
indianexpress.com
Anupreet Randhawa Arrest Land Acquisition Embezzlement Case
economictimes.indiatimes.com
Petrol Diesel Price Hike Rs 3 Per Litre India Food Inflation Retail Growth Iran War Impact Rbi Crude Oil
finance.yahoo.com
Polypid Pypd Q1 2026 Earnings
finance.yahoo.com